Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled dose-ranging study of evinacumab in persistent hypercholesterolemia
NL-OMON48629Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of evinacumab in hypercholesterolemia and familial hypercholesterolemia (FH) (7 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Primary efficacy endpoint. Started May 2018; status: completed.
02
Drugs
evinacumab
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NL-OMON48629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48629.